Selected research
Market Outlook & Growth Opportunities
Global Cell Therapy CDMO Market Outlook and Growth Opportunities 2026
Market perspective
The global Cell Therapy CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Cell Therapy CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Cell Therapy CDMO market include Catalent, Lonza, Charles River, FUJIFILM Diosynth Biotechnologies, Exothera, Pharmaron, OBiO, AGC Biologics and Cytiva, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Cell Therapy CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cell Therapy CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cell Therapy CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cell Therapy CDMO market.
Cell Therapy CDMO Segment by Company
Catalent
Lonza
Charles River
FUJIFILM Diosynth Biotechnologies
Exothera
Pharmaron
OBiO
AGC Biologics
Cytiva
ThermoGenesis
eXmoor Pharma
Advanced Therapies
Catalent Biologics
Patheon Pharma Services
Sartorius
Genezen
The Discovery Labs
Cell Therapy CDMO Segment by Type
Autologous Cell Therapy CDMO
Allogeneic Cell Therapy CDMO
Viral Vector and Gene Editing CDMO
Cell Therapy CDMO Segment by Application
Commercial
Academic Research
Others
Cell Therapy CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Cell Therapy CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Cell Therapy CDMO key companies, revenue, market share, and recent developments.
3. To split the Cell Therapy CDMO breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Cell Therapy CDMO market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Cell Therapy CDMO significant trends, drivers, influence factors in global and regions.
6. To analyze Cell Therapy CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Therapy CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell Therapy CDMO industry.
Chapter 3: Detailed analysis of Cell Therapy CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Cell Therapy CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Cell Therapy CDMO in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Cell Therapy CDMO Industry Trends
Table 2. Cell Therapy CDMO Industry Drivers
Table 3. Cell Therapy CDMO Industry Opportunities and Challenges
Table 4. Cell Therapy CDMO Industry Restraints
Table 5. Global Cell Therapy CDMO Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Cell Therapy CDMO Revenue Share by Company (2021-2026)
Table 7. Global Cell Therapy CDMO Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Cell Therapy CDMO Key Company Manufacturing Base & Headquarters
Table 9. Global Cell Therapy CDMO Company, Product Type & Application
Table 10. Global Cell Therapy CDMO Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Cell Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Autologous Cell Therapy CDMO
Table 15. Significant Companies of Allogeneic Cell Therapy CDMO
Table 16. Significant Companies of Viral Vector and Gene Editing CDMO
Table 17. Global Cell Therapy CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 18. Global Cell Therapy CDMO Sales Value by Type (2021-2026) & (US$ Million)
Table 19. Global Cell Therapy CDMO Sales Value by Type (2027-2032) & (US$ Million)
Table 20. Global Cell Therapy CDMO Sales Value Share by Type (2021-2026)
Table 21. Global Cell Therapy CDMO Sales Value Share by Type (2027-2032)
Table 22. Significant Companies of Commercial
Table 23. Significant Companies of Academic Research
Table 24. Significant Companies of Others
Table 25. Global Cell Therapy CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 26. Global Cell Therapy CDMO Sales Value by Application (2021-2026) & (US$ Million)
Table 27. Global Cell Therapy CDMO Sales Value by Application (2027-2032) & (US$ Million)
Table 28. Global Cell Therapy CDMO Sales Value Share by Application (2021-2026)
Table 29. Global Cell Therapy CDMO Sales Value Share by Application (2027-2032)
Table 30. Global Cell Therapy CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. Global Cell Therapy CDMO Sales Value by Region (2021-2026) & (US$ Million)
Table 32. Global Cell Therapy CDMO Sales Value Share by Region (2021-2026)
Table 33. Global Cell Therapy CDMO Sales Value by Region (2027-2032) & (US$ Million)
Table 34. Global Cell Therapy CDMO Sales Value Share by Region (2027-2032)
Table 35. Global Cell Therapy CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 36. Global Cell Therapy CDMO Sales Value by Country (2021-2026) & (US$ Million)
Table 37. Global Cell Therapy CDMO Sales Value Market Share by Country (2021-2026)
Table 38. Global Cell Therapy CDMO Sales Value by Country (2027-2032) & (US$ Million)
Table 39. Global Cell Therapy CDMO Sales Value Market Share by Country (2027-2032)
Table 40. Catalent Company Information
Table 41. Catalent Business Overview
Table 42. Catalent Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 43. Catalent Cell Therapy CDMO Product Portfolio
Table 44. Catalent Recent Development
Table 45. Lonza Company Information
Table 46. Lonza Business Overview
Table 47. Lonza Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 48. Lonza Cell Therapy CDMO Product Portfolio
Table 49. Lonza Recent Development
Table 50. Charles River Company Information
Table 51. Charles River Business Overview
Table 52. Charles River Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Charles River Cell Therapy CDMO Product Portfolio
Table 54. Charles River Recent Development
Table 55. FUJIFILM Diosynth Biotechnologies Company Information
Table 56. FUJIFILM Diosynth Biotechnologies Business Overview
Table 57. FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 58. FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Product Portfolio
Table 59. FUJIFILM Diosynth Biotechnologies Recent Development
Table 60. Exothera Company Information
Table 61. Exothera Business Overview
Table 62. Exothera Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 63. Exothera Cell Therapy CDMO Product Portfolio
Table 64. Exothera Recent Development
Table 65. Pharmaron Company Information
Table 66. Pharmaron Business Overview
Table 67. Pharmaron Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. Pharmaron Cell Therapy CDMO Product Portfolio
Table 69. Pharmaron Recent Development
Table 70. OBiO Company Information
Table 71. OBiO Business Overview
Table 72. OBiO Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 73. OBiO Cell Therapy CDMO Product Portfolio
Table 74. OBiO Recent Development
Table 75. AGC Biologics Company Information
Table 76. AGC Biologics Business Overview
Table 77. AGC Biologics Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 78. AGC Biologics Cell Therapy CDMO Product Portfolio
Table 79. AGC Biologics Recent Development
Table 80. Cytiva Company Information
Table 81. Cytiva Business Overview
Table 82. Cytiva Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. Cytiva Cell Therapy CDMO Product Portfolio
Table 84. Cytiva Recent Development
Table 85. ThermoGenesis Company Information
Table 86. ThermoGenesis Business Overview
Table 87. ThermoGenesis Cell Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. ThermoGenesis Cell Therapy CDMO Product Portfolio
Table 89. ThermoGenesis Recent Development
Table 90. eXmoor Pharma Company Information
Table 91. eXmoor Pharma Business Overview
Table 92. eXmoor Pharma Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 93. eXmoor Pharma Cell Therapy CDMO Product Portfolio
Table 94. eXmoor Pharma Recent Development
Table 95. Advanced Therapies Company Information
Table 96. Advanced Therapies Business Overview
Table 97. Advanced Therapies Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 98. Advanced Therapies Cell Therapy CDMO Product Portfolio
Table 99. Advanced Therapies Recent Development
Table 100. Catalent Biologics Company Information
Table 101. Catalent Biologics Business Overview
Table 102. Catalent Biologics Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 103. Catalent Biologics Cell Therapy CDMO Product Portfolio
Table 104. Catalent Biologics Recent Development
Table 105. Patheon Pharma Services Company Information
Table 106. Patheon Pharma Services Business Overview
Table 107. Patheon Pharma Services Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 108. Patheon Pharma Services Cell Therapy CDMO Product Portfolio
Table 109. Patheon Pharma Services Recent Development
Table 110. Sartorius Company Information
Table 111. Sartorius Business Overview
Table 112. Sartorius Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 113. Sartorius Cell Therapy CDMO Product Portfolio
Table 114. Sartorius Recent Development
Table 115. Genezen Company Information
Table 116. Genezen Business Overview
Table 117. Genezen Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 118. Genezen Cell Therapy CDMO Product Portfolio
Table 119. Genezen Recent Development
Table 120. The Discovery Labs Company Information
Table 121. The Discovery Labs Business Overview
Table 122. The Discovery Labs Cell Therapy CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 123. The Discovery Labs Cell Therapy CDMO Product Portfolio
Table 124. The Discovery Labs Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Authors List of This Report
Table 127. Secondary Sources
Table 128. Primary Sources
List of Figures
Figure 1. Cell Therapy CDMO Product Image
Figure 2. Global Cell Therapy CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Cell Therapy CDMO Market Size (2021-2032) & (US$ Million)
Figure 4. Global Cell Therapy CDMO Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Autologous Cell Therapy CDMO Image
Figure 8. Allogeneic Cell Therapy CDMO Image
Figure 9. Viral Vector and Gene Editing CDMO Image
Figure 10. Global Cell Therapy CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 11. Global Cell Therapy CDMO Sales Value Share 2021 VS 2025 VS 2032
Figure 12. Global Cell Therapy CDMO Sales Value Share by Type (2021-2032)
Figure 13. Commercial Image
Figure 14. Academic Research Image
Figure 15. Others Image
Figure 16. Global Cell Therapy CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 17. Global Cell Therapy CDMO Sales Value Share 2021 VS 2025 VS 2032
Figure 18. Global Cell Therapy CDMO Sales Value Share by Application (2021-2032)
Figure 19. Global Cell Therapy CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 20. Global Cell Therapy CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 21. North America Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 22. North America Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 23. Europe Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 24. Europe Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 25. Asia-Pacific Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 26. Asia-Pacific Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 27. South America Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 28. South America Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 29. Middle East & Africa Cell Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 30. Middle East & Africa Cell Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 31. USA Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 32. USA Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 33. USA Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 34. Canada Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 35. Canada Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 36. Canada Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 37. Mexico Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 38. Mexico Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 39. Mexico Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 40. Germany Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 41. Germany Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 42. Germany Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 43. France Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 44. France Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 45. France Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 46. U.K. Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 47. U.K. Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 48. U.K. Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 49. Italy Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 50. Italy Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 51. Italy Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 52. Spain Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 53. Spain Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 54. Spain Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 55. Russia Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 56. Russia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 57. Russia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 58. Netherlands Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 59. Netherlands Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 60. Netherlands Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 61. Nordic Countries Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 62. Nordic Countries Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 63. Nordic Countries Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 64. China Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 65. China Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 66. China Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 67. Japan Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 68. Japan Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 69. Japan Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 70. South Korea Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 71. South Korea Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 72. South Korea Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 73. India Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 74. India Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 75. India Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 76. Australia Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 77. Australia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 78. Australia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 79. Southeast Asia Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 80. Southeast Asia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 81. Southeast Asia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 82. Brazil Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 83. Brazil Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 84. Brazil Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 85. Argentina Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 86. Argentina Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 87. Argentina Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 88. Chile Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 89. Chile Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 90. Chile Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 91. Colombia Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 92. Colombia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 93. Colombia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 94. Peru Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 95. Peru Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 96. Peru Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 97. Saudi Arabia Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 98. Saudi Arabia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 99. Saudi Arabia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 100. Israel Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 101. Israel Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 102. Israel Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 103. UAE Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 104. UAE Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 105. UAE Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 106. Turkey Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 107. Turkey Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 108. Turkey Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 109. Iran Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 110. Iran Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 111. Iran Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 112. Egypt Cell Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 113. Egypt Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 114. Egypt Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 115. Years Considered
Figure 116. Research Process
Figure 117. Key Executives Interviewed
Scope & coverage.
Types
- Autologous Cell Therapy CDMO
- Allogeneic Cell Therapy CDMO
- Viral Vector and Gene Editing CDMO
Applications
- Commercial
- Academic Research
- Others
Companies covered
- Catalent
- Lonza
- Charles River
- FUJIFILM Diosynth Biotechnologies
- Exothera
- Pharmaron
- OBiO
- AGC Biologics
- Cytiva
- ThermoGenesis
- eXmoor Pharma
- Advanced Therapies
- Catalent Biologics
- Patheon Pharma Services
- Sartorius
- Genezen
- The Discovery Labs
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Cell Therapy CDMO Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Cell Therapy CDMO Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Cell Therapy CDMO Market Dynamics
- 2.1 Cell Therapy CDMO Industry Trends
- 2.2 Cell Therapy CDMO Industry Drivers
- 2.3 Cell Therapy CDMO Industry Opportunities and Challenges
- 2.4 Cell Therapy CDMO Industry Restraints
3 Cell Therapy CDMO Market by Company
- 3.1 Global Cell Therapy CDMO Company Revenue Ranking in 2025
- 3.2 Global Cell Therapy CDMO Revenue by Company (2021-2026)
- 3.3 Global Cell Therapy CDMO Company Ranking (2024-2026)
- 3.4 Global Cell Therapy CDMO Company Manufacturing Base and Headquarters
- 3.5 Global Cell Therapy CDMO Company Product Type and Application
- 3.6 Global Cell Therapy CDMO Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Cell Therapy CDMO Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Cell Therapy CDMO Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Cell Therapy CDMO Market by Type
- 4.1 Cell Therapy CDMO Type Introduction
- 4.1.1 Autologous Cell Therapy CDMO
- 4.1.2 Allogeneic Cell Therapy CDMO
- 4.1.3 Viral Vector and Gene Editing CDMO
- 4.2 Global Cell Therapy CDMO Sales Value by Type
- 4.2.1 Global Cell Therapy CDMO Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Cell Therapy CDMO Sales Value by Type (2021-2032)
- 4.2.3 Global Cell Therapy CDMO Sales Value Share by Type (2021-2032)
5 Cell Therapy CDMO Market by Application
- 5.1 Cell Therapy CDMO Application Introduction
- 5.1.1 Commercial
- 5.1.2 Academic Research
- 5.1.3 Others
- 5.2 Global Cell Therapy CDMO Sales Value by Application
- 5.2.1 Global Cell Therapy CDMO Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Cell Therapy CDMO Sales Value by Application (2021-2032)
- 5.2.3 Global Cell Therapy CDMO Sales Value Share by Application (2021-2032)
6 Cell Therapy CDMO Regional Value Analysis
- 6.1 Global Cell Therapy CDMO Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cell Therapy CDMO Sales Value by Region (2021-2032)
- 6.2.1 Global Cell Therapy CDMO Sales Value by Region: 2021-2026
- 6.2.2 Global Cell Therapy CDMO Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Cell Therapy CDMO Sales Value (2021-2032)
- 6.3.2 North America Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Cell Therapy CDMO Sales Value (2021-2032)
- 6.4.2 Europe Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Cell Therapy CDMO Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Cell Therapy CDMO Sales Value (2021-2032)
- 6.6.2 South America Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Cell Therapy CDMO Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Cell Therapy CDMO Sales Value Share by Country, 2025 VS 2032
7 Cell Therapy CDMO Country-level Value Analysis
- 7.1 Global Cell Therapy CDMO Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Cell Therapy CDMO Sales Value by Country (2021-2032)
- 7.2.1 Global Cell Therapy CDMO Sales Value by Country (2021-2026)
- 7.2.2 Global Cell Therapy CDMO Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.7.2 France Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.14.2 China Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.17.2 India Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Cell Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Cell Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Cell Therapy CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Catalent
- 8.1.1 Catalent Company Information
- 8.1.2 Catalent Business Overview
- 8.1.3 Catalent Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.1.4 Catalent Cell Therapy CDMO Product Portfolio
- 8.1.5 Catalent Recent Developments
- 8.2 Lonza
- 8.2.1 Lonza Company Information
- 8.2.2 Lonza Business Overview
- 8.2.3 Lonza Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.2.4 Lonza Cell Therapy CDMO Product Portfolio
- 8.2.5 Lonza Recent Developments
- 8.3 Charles River
- 8.3.1 Charles River Company Information
- 8.3.2 Charles River Business Overview
- 8.3.3 Charles River Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.3.4 Charles River Cell Therapy CDMO Product Portfolio
- 8.3.5 Charles River Recent Developments
- 8.4 FUJIFILM Diosynth Biotechnologies
- 8.4.1 FUJIFILM Diosynth Biotechnologies Company Information
- 8.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 8.4.3 FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.4.4 FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Product Portfolio
- 8.4.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 8.5 Exothera
- 8.5.1 Exothera Company Information
- 8.5.2 Exothera Business Overview
- 8.5.3 Exothera Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.5.4 Exothera Cell Therapy CDMO Product Portfolio
- 8.5.5 Exothera Recent Developments
- 8.6 Pharmaron
- 8.6.1 Pharmaron Company Information
- 8.6.2 Pharmaron Business Overview
- 8.6.3 Pharmaron Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.6.4 Pharmaron Cell Therapy CDMO Product Portfolio
- 8.6.5 Pharmaron Recent Developments
- 8.7 OBiO
- 8.7.1 OBiO Company Information
- 8.7.2 OBiO Business Overview
- 8.7.3 OBiO Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.7.4 OBiO Cell Therapy CDMO Product Portfolio
- 8.7.5 OBiO Recent Developments
- 8.8 AGC Biologics
- 8.8.1 AGC Biologics Company Information
- 8.8.2 AGC Biologics Business Overview
- 8.8.3 AGC Biologics Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.8.4 AGC Biologics Cell Therapy CDMO Product Portfolio
- 8.8.5 AGC Biologics Recent Developments
- 8.9 Cytiva
- 8.9.1 Cytiva Company Information
- 8.9.2 Cytiva Business Overview
- 8.9.3 Cytiva Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.9.4 Cytiva Cell Therapy CDMO Product Portfolio
- 8.9.5 Cytiva Recent Developments
- 8.10 ThermoGenesis
- 8.10.1 ThermoGenesis Company Information
- 8.10.2 ThermoGenesis Business Overview
- 8.10.3 ThermoGenesis Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.10.4 ThermoGenesis Cell Therapy CDMO Product Portfolio
- 8.10.5 ThermoGenesis Recent Developments
- 8.11 eXmoor Pharma
- 8.11.1 eXmoor Pharma Company Information
- 8.11.2 eXmoor Pharma Business Overview
- 8.11.3 eXmoor Pharma Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.11.4 eXmoor Pharma Cell Therapy CDMO Product Portfolio
- 8.11.5 eXmoor Pharma Recent Developments
- 8.12 Advanced Therapies
- 8.12.1 Advanced Therapies Company Information
- 8.12.2 Advanced Therapies Business Overview
- 8.12.3 Advanced Therapies Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.12.4 Advanced Therapies Cell Therapy CDMO Product Portfolio
- 8.12.5 Advanced Therapies Recent Developments
- 8.13 Catalent Biologics
- 8.13.1 Catalent Biologics Company Information
- 8.13.2 Catalent Biologics Business Overview
- 8.13.3 Catalent Biologics Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.13.4 Catalent Biologics Cell Therapy CDMO Product Portfolio
- 8.13.5 Catalent Biologics Recent Developments
- 8.14 Patheon Pharma Services
- 8.14.1 Patheon Pharma Services Company Information
- 8.14.2 Patheon Pharma Services Business Overview
- 8.14.3 Patheon Pharma Services Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.14.4 Patheon Pharma Services Cell Therapy CDMO Product Portfolio
- 8.14.5 Patheon Pharma Services Recent Developments
- 8.15 Sartorius
- 8.15.1 Sartorius Company Information
- 8.15.2 Sartorius Business Overview
- 8.15.3 Sartorius Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.15.4 Sartorius Cell Therapy CDMO Product Portfolio
- 8.15.5 Sartorius Recent Developments
- 8.16 Genezen
- 8.16.1 Genezen Company Information
- 8.16.2 Genezen Business Overview
- 8.16.3 Genezen Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.16.4 Genezen Cell Therapy CDMO Product Portfolio
- 8.16.5 Genezen Recent Developments
- 8.17 The Discovery Labs
- 8.17.1 The Discovery Labs Company Information
- 8.17.2 The Discovery Labs Business Overview
- 8.17.3 The Discovery Labs Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.17.4 The Discovery Labs Cell Therapy CDMO Product Portfolio
- 8.17.5 The Discovery Labs Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst